Background: Gynecological malignancy is one of the commonest malignancies worldwide and an important cause of cancer morbidity and mortality worldwide. Cervical, endometrial and ovarian cancers are relatively more common, whereas vulval, vaginal, fallopian tube cancers and choriocarcinoma are very rare. Despite the high frequency of some female genital tumors in our environment, there is paucity of literature on the subject. Therefore, this study was designed to provide information regarding the pattern of gynecological malignancies and their relative frequencies in relation to age and sites of female genital tract. Methods: This was a teaching hospital based retrospective study over a period of two years consisting of a total of 52 malignant cases. Results: The most common site of involvement was cervix(50%) followed by ovary( 36.5%),corpus uteri(11.5%) and vagina(2%). No case of vulval or fallopian tube cancer was seen. Cervical carcinoma was more common in 4th and 5th decade of life. Majority of the cervical cancers were squamous cell carcinomas followed in frequency by adenosquamous carcinomas and adenocarcinomas. Amongst the ovarian cancer cases, maximum age incidence was found in 41–50 years followed by 21–30 years. Most of the ovarian cancers were mucinous cystadenocarcinomas followed by serous cystadenocarcinomas and metastatic ovarian tumours. Out of total 6 cases of cancer of corpus uteri, three were endometrial adenocarcinomas and three were low grade endo metrial sarcomas. All the endometrial adenocarcinomas were seen after 40 years of age where as ,sarcomas were predominantly seen in age < 30 years. Only one case of vaginal ca was seen in two years. Conclusion: In this cross sectional study, we found more cervical cancer than other gynaecological malignancies Cervical cancer is largely a preventable disease. There is the need to increase public awareness on the risk factors and the Government and non–governmental bodies should establish sustainable national and regional cervical cancer screening programs and ensure HPV vaccine available and affordable to the women.